Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000434593 | SCV000512937 | uncertain significance | not provided | 2023-08-03 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Invitae | RCV000536343 | SCV000636472 | uncertain significance | Progressive myoclonic epilepsy | 2022-11-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 48 of the EPM2A protein (p.Gly48Asp). This variant is present in population databases (no rsID available, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with EPM2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 377829). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Center for Genomics, |
RCV000768208 | SCV000898672 | uncertain significance | Lafora disease | 2021-03-30 | criteria provided, single submitter | clinical testing | EPM2A NM_005670.3 exon 1 p.Gly48Asp (c.143G>A):This variant has not been reported in the literature but is present in 8/29388 European alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This variant is present in ClinVar (Variation ID:377829). Evolutionary conservation and computational predictive tools for this variant are limited or unavailable. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. |
Athena Diagnostics Inc | RCV000434593 | SCV001143864 | uncertain significance | not provided | 2018-09-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392951 | SCV002702894 | uncertain significance | Inborn genetic diseases | 2020-06-01 | criteria provided, single submitter | clinical testing | The p.G48D variant (also known as c.143G>A), located in coding exon 1 of the EPM2A gene, results from a G to A substitution at nucleotide position 143. The glycine at codon 48 is replaced by aspartic acid, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |